



References

- Aziz M.F, Andrijono dan Saifuddin A.B. 2006, Buku acuan nasional onkologi ginekologi, 1th ed. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo, 468-527
- Baeriswyl, V. and Christofori, G., 2009, October. The angiogenic switch in carcinogenesis. In *Seminars in cancer biology* (Vol. 19, No. 5, pp. 329-337). Academic Press.
- Barber, Hugh R.K, Edward A Graber, Tae Hae Kwon. *CA Cancer J Clin: Ovarian carcinoma*. 2009. May 15; 24;339-347
- Cramer, D. W., & Welch, W. R. (1983). Determinants in ovarian carcinoma risk. II. Inferences regarding pathogenesis. *Journal of the National Cancer Institute*, 71(4), 717-721.
- Ding, X.Y., Ding, J., Wu, K., Wen, W., Liu, C., Yan, H.X., Chen, C., Wang, S., Tang, H., Gao, C.K. and Guo, L.N., 2012. Cross-talk between endothelial cells and tumor via delta-like ligand4/Notch/PTEN signaling inhibits lung cancer growth. *Oncogene*, 31(23), pp.2899-2906. NCBI
- Eroschenko, V.P. and Di Fiore, M.S., 2013. *DiFiore's atlas of histology with functional correlations*. Lippincott Williams & Wilkins
- Fathalla, M.F. *et al.*, 2013, 'Incessant ovulation and ovarian carcinoma – a hypothesis re-visited', *Facts, Views & Vision in OBGYN*, vol.5, no.4, pp.292-7.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. and Bray, F., 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International journal of cancer*, 136(5).
- Goff, B.A., Mandel, L.S., Melancon, C.H. and Muntz, H.G., 2004. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. *Jama*, 291(22), pp.2705-2712.
- Holderfield, Matthew T. *et Hughes*, Christopher C.W., 2008, 'Crosstalk Between Vascular Endothelial Growth Factor, Notch, and Transforming Growth Factor- β in Vascular Morphogenesis', *Circulation Research*, vol.2008, no.102, pp.637-52
- Hopfer, O., Zwahlen, D., Fey, M.F. and Aebi, S., 2005. The Notch pathway in ovarian carcinomas and adenomas. *British journal of cancer*, 93(6), pp.709-718.
- Hu, W., Lu, C., Dong, H.H., Huang, J., Shen, D.Y., Stone, R.L., Nick, A.M., Shahzad, M.M., Mora, E., Jennings, N.B. and Lee, S.J., 2011. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. *Cancer research*, 71(18), pp.6030-6039.
- Ismael, S. and Sastroasmoro, S., 2005. Dasar-dasar metodologi penelitian klinis. Jakarta: *Bagian Ilmu Kesehatan Anak FK Universitas Indonesia*
- Jakobsson, L., Bentley, K. and Gerhardt, H., 2009. VEGFRs and Notch: a dynamic collaboration in vascular patterning.
- Kofler, Natalie M. *et al.*, 2011, 'Notch Signaling in Developmental and Tumor Angiogenesis', *Gene & Cancer*, vol.2, no.12, pp.1106-16.



- Koshiyama, M., Matsumura, N., & Konishi, I. (2014). Recent Concepts of Ovarian Carcinogenesis: Type I and Type II. *BioMed Research International*, 2014
- Kumar, V., Abbas, A. K., & Aster, J. C. (2013). *Endocrine system. Robbins Basic Pathology*
- Landen, C.N., Birrer, M.J. and Sood, A.K. (2008) 'Early events in the pathogenesis of Epithelial ovarian carcinoma', *Journal of Clinical Oncology*, 26(6), pp. 995–1005. doi: 10.1200/jco.2006.07.9970.
- Montes, A.F., Gómez, J.G., Mata, J.G., Bermejo, M.A., Viejo, M.N. and Urrutia, S.A., 2012. *Epidemiology and Etiology of Ovarian Cancer*. INTECH Open Access Publisher
- Moore, K.L., Dalley, A.F. and Agur, A.M., 2013. *Clinically oriented anatomy*. Lippincott Williams & Wilkins.
- Mutch, D.G. and Prat, J. (2014) '2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer', *Gynecologic Oncology*, 133(3), pp. 401–404. doi: 10.1016/j.ygyno.2014.04.013.
- Petrucelli, N., Daly, M.B. and Pal, T., 2016. BRCA1-and BRCA2-associated hereditary breast and ovarian cancer.
- Pradhatmo, H., 2015. Methylation status and expression of BRCA2 in epithelial ovarian cancers in Indonesia. *Asian Pac J Cancer Prev*, 16(18), pp.8599-8604.
- Razi, Saeid et al. "The Incidence and Mortality of Ovarian Cancer and Their Relationship with the Human Development Index in Asia." *ecancermedicalscience* 10 (2016): 628. *PMC*. Web. 11 Oct. 2017.
- Rossing, M.A., Cushing-Haugen, K.L., Wicklund, K.G. and Weiss, N.S., 2008. Cigarette smoking and risk of epithelial ovarian cancer. *Cancer causes & control*, 19(4), pp.413-420.
- Russo, A., Calò, V., Bruno, L., Rizzo, S., Bazan, V. and Di Fede, G., 2009. Hereditary ovarian cancer. *Critical reviews in oncology/hematology*, 69(1), pp.28-44.
- Spannuth, W.A., Nick, A.M., Jennings, N.B., Armaiz-Pena, G.N., Mangala, L.S., Danes, C.G., Lin, Y.G., Merritt, W.M., Thaker, P.H., Kamat, A.A. and Han, L.Y., 2009. Functional significance of VEGFR-2 on ovarian cancer cells. *International journal of cancer*, 124(5), pp.1045-1053.
- Tuefferd, M., Couturier, J., Penault-Llorca, F., Vincent-Salomon, A., Broët, P., Guastalla, J.P., Allouache, D., Combe, M., Weber, B., Pujade-Lauraine, E. and Camilleri-Broët, S., 2007. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. *PloS one*, 2(11), p.e1138.
- Wan-Ching Yen, Marcus M. Fischer, Jalpa Shah, Jie Wei, Jennifer Cain, Pete Yeung, Lucia Beviglia, Belinda Cancilla, Ann Kapoun, John Lewicki, Austin Gurney, Timothy Hoey. Anti-DLL4 (demcizumab) inhibits tumor growth and reduces cancer stem cell frequency in patient-derived ovarian cancer xenografts. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3725. doi:10.1158/1538-7445.AM2013-3725



- World Health Organization. 2017. *Cancer*. [ONLINE] Available at: <http://www.who.int/mediacentre/factsheets/fs297/en/>. [Accessed 11 October 2017]
- Zhang, Y., Coogan, P.F., Palmer, J.R., Strom, B.L. and Rosenberg, L., 2004. Cigarette smoking and increased risk of mucinous epithelial ovarian cancer. *American journal of epidemiology*, 159(2), pp. 133-139.